Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Easton Pharmaceuticals launches first three OTC products
Easton is pleased to announce that its first 3 main OTC products (Viorra, Skin Renou HA and Kenestrin Gel) are now ready to be ordered directly through its
Easton is pleased to announce that its first 3 main OTC products (Viorra, Skin Renou HA and Kenestrin Gel) are now ready to be ordered directly through its
LOWR HDV – 1 (LOnafarnib With and without Ritonavir-1) is a parallel dose comparison study which randomized subjects to receive different doses of lonafarnib with or without ritonavir
The results will also appear in forthcoming print issues of the journals. Merck acquired ZERBAXA as a part of its purchase of Cubist Pharmaceuticals. The publications report the
The safety profile observed in this trial is consistent with other trials of Arzerra and no new safety signals were observed. "Patients eventually stop responding to current CLL
Caliber’s production will be used for IND-enabling toxicology studies and initial human clinical trials of IBIO-CFB03. iBio is the exclusive worldwide licensee of the patents developed by Dr.
The subject patent claims cover CBDV, a non-psychoactive cannabinoid extracted from the cannabis plant, for use in the treatment of patients with epilepsy and specifically for the control
Syndax’s entinostat is an oral, highly selective histone deacetylase (HDAC) inhibitor, while Keytruda is Merck’s first anti-PD-1 therapy approved in the US. Keytruda is a humanized monoclonal antibody
The Emergent-developed MOR209/ES414 molecule is an immunotherapeutic protein, which has shown in preclinical in vitro and in vivo studies its ability to redirect T-cell cytotoxicity towards cells expressing
Sandoz, a Novartis company, is the first in the US to receive the approval through the new FDA biosimilars pathway established under the Biologics Price Competition and Innovation
As part of the deal, GSK’s existing opiates business including related manufacturing sites in Latrobe (Tasmania) and Port Fairy (Victoria), and its portfolio of opiates products along with